Search - tctmd.com

Displaying 1 - 20 of 42

Sort: Relevancy | Date

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Presenter: Marc P. Bonaca

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

L.A. McKeown

April 12, 2024

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Caitlin E. Cox

April 10, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

Todd Neale

March 09, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

Presentation ACC 2023

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Presenter: Neha J. Pagidipati

March 05, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

Todd Neale

May 15, 2021

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

L.A. McKeown

May 15, 2021

Advertisement

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

What’s Going to Be Hot at ACC 2025?

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Low 1-Year Stroke Risk After Commercial Watchman Use

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content